Ramsay Health Care Limited (ASX:RHC) entered into an agreement to acquire Elysium Healthcare Limited from BC Partners for an enterprise value of approximately £780 million on December 13, 2021. The enterprise value representing FY21 EV/EBITDA multiple of 13.5 and amount to be funded through Ramsay's existing debt facilities. Elysium Healthcare reported EBITDA of £57.4 million in the year ending June 30, 2021. Elysium and Ramsay will run independently of each other and Joy Chamberlain will remain as chief executive officer of Elysium following completion. The transaction is expected to complete during Q1 2022. The transaction is expected to deliver mid-single digit EPS accretion in FY23. Stephen Atkinson, Andrew Clarke and Alexandra Kamerling of DLA Piper acted as legal advisor to Ramsay. Adam Orr and Hannah Manning of Travers Smith acted as legal advisors for the senior management team of Elysium Healthcare. Deutsche Bank Securities acted as Financial advisor to Ramsay Health Care Limited. Morgan acted as financial advisor to BC Partners.

Ramsay Health Care Limited (ASX:RHC) completed the acquisition of Elysium Healthcare Limited from BC Partners on February 1, 2022.